Flexion Therapeutics

10 Mall Road, Suite 301, Burlington MA  01803

www.flexiontherapeutics.com

info@flexiontherapeutics.com

781.305.7777

January 16, 2020

Melissa Layman

[Address]

Dear Melissa:

We are pleased to offer you employment with Flexion Therapeutics, Inc. (the "Company") as Chief Commercial Officer reporting to Michael Clayman, Chief Executive Officer. Your start date is anticipated to be March 12, 2020 (“Start Date”).

Initial Compensation: Your initial compensation package includes the following:

(1) Subject to Board approval, you will be granted an option (the “Option”) under the Company’s equity incentive plan in place at the time of grant (the "Plan"), to purchase 30,000 shares of common stock of the Company at an exercise price per share equal to the fair market value per share of the Company's common stock on the date of grant. Subject to your Continuous Service (as defined in the Plan) through each vesting date, the Option will vest as to 25% of the shares of common stock underlying such Option on the one year anniversary of your employment commencement date and as to 1/48th of the shares of common stock underlying such Option in equal monthly installments on the last day of each month thereafter, so that all of the shares subject to the Option will vest four years from the anniversary of your employment commencement date.   All other terms, conditions, and limitations of the Option will be set forth in a stock option grant notice, the Company's standard stock option agreement and the Plan (collectively, the “Stock Option Documents,” which shall govern your Option).  To the extent there

1

February 2019

is a conflict between this Agreement and the Stock Option Documents, the Stock Option Documents shall govern.

(2) In addition, subject to Board approval, you will be granted under the Plan 61,000 restricted stock units (“RSUs”).  Subject to your Continuous Service through each vesting date, 25% of the shares of common stock subject to the RSUs will vest on each anniversary of your employment commencement date so that all of the shares subject to the RSU will vest four years from the anniversary of your employment commencement date.  All other terms, conditions, and limitations of the RSUs will be set forth in a Restricted Stock Unit Grant Notice, the Company's Restricted Stock Unit Award Agreement and the Plan (collectively, the “RSU Documents,” which shall govern your RSUs).  To the extent there is a conflict between this Agreement and the RSU Documents, the RSU Documents shall govern.

(3) In addition, subject to Board approval, you will be granted under the Plan 30,000 performance based restricted stock units (“PSUs”).  Subject to your Continuous Service with the Company through each vesting date and the achievement of the vesting milestones, 25% of the shares of common stock subject to the PSUs will vest in 2021 upon the Compensation Committee of the Board’s confirmation of your achievement of the vesting milestones and thereafter on January 1 of the subsequent three years so that all of the shares subject to the PSU will have vested on January 1, 2024.   All other terms, conditions, and limitations of the PSUs will be set forth in a Restricted Stock Unit Grant Notice, the Company's Restricted Stock Unit Award Agreement and the Plan (collectively, the “RSU Documents,” which shall govern your RSUs).  To the extent there is a conflict between this Agreement and the RSU Documents, the RSU Documents shall govern.

(ii) $50,000 (less applicable taxes) to be paid to you six (6) months following your Start Date (on or about September 18, 2020); and

(iii) $50,000 (less applicable taxes) to be paid to you on the one (1) year anniversary of your Start Date (on or about March 19, 2021).

These three additional payments are referred to as the “Additional Bonuses.” To be eligible for these Additional Bonuses you must be employed and in good standing as the Chief Commercial Officer on the specified payment dates and be in full compliance with your Proprietary Information Agreement (as defined herein).

“Cause” means with respect to such employee, the occurrence of any of the following events: (i) such employee’s commission of any felony or any crime involving fraud; (ii) such employee’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such employee’s intentional, material violation of any contract or agreement between the employee and the Company or of any statutory duty owed to the

2

February 2019

Company; (iv) such employee’s repeated and willful failure to satisfactorily perform such employee’s job duties after written notice of such deficiency and an opportunity to cure or; (v) such employee’s engaging or participating in any activity which is directly competitive with or injurious to the Company or which violates any material provisions of Company’s policies or employee’s Proprietary Information and Inventions Agreement with the Company. The determination whether a termination is for Cause shall be made by the Company in its sole and exclusive judgment and discretion.

Benefits:  You will be eligible to participate on the same basis as similarly situated employees in the Company's benefit plans in effect from time to time during your employment.  All matters of eligibility for coverage or employee benefits under any benefit plan shall be determined in accordance with the provisions of such plan. For a more detailed understanding of the Company’s benefits and the eligibility requirements, please consult the policies and summary plan descriptions for the programs which will be made available to you.  Please note that the Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion.  

At-Will Employment; Certain Conditions of Employment:  Your employment with the Company will be “at will,” which means that the Company may modify the terms of employment at any time, and either you or the Company may terminate your employment at any time for any or no reason, with or without prior notice.  Along these same lines, please note that nothing in this offer letter is a promise or guarantee of employment for any specific period of time or for continued employment.

Please be advised that this offer is contingent on: (a) your executing this offer letter within the time set forth herein and a Proprietary Information, Inventions, Non-Solicitation, and Non-Competition Agreement (“PIIA”); and (b) your satisfying the eligibility requirements for employment in the United States; and (c) your satisfying a background and reference checks.

In addition to the above, by signing this letter you are representing that you have full authority to accept this position and perform the duties of the position without conflict with any other obligations, and that you are not involved in any situation that might create, or appear to create, a conflict of interest with respect to your loyalty to or duties for the Company. You specifically warrant that you are not subject to an employment agreement or restrictive covenant preventing full performance of your duties to the Company. You agree not to bring to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former employer for their possession and use. You also agree to honor all obligations to former employers during your employment with the Company.

You further acknowledge that the Board has determined that you will be performing significant policy-making functions for the Company and shall therefore be regarded as a Section 16 officer of the Company pursuant to Section 16(a) of the Securities Exchange Act (“Section 16 Officer”).  For so long as the Board continues to regard you as a Section 16 Officer, you acknowledge your obligation to make certain periodic filings with the SEC, including but not limited to, the “Initial Statement of Beneficial Ownership of Securities” on Form 3 and the “Statement of Changes of Beneficial Ownership of Securities” on SEC Form 4.  You represent and warrant that you will timely comply with all obligations relating to your role as a Section 16 Officer.  

Severance Eligibility: Subject to the other provisions of this Agreement, upon termination of your employment, the Company shall pay your base salary and accrued and unused vacation benefits earned

3

February 2019

through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings (the “Accrued Obligations”).  In addition, you will be eligible for the following severance benefits if your employment is terminated under the circumstances described below.

If the Company (or its successor) terminates your employment without Cause (as defined below) or if you terminate your employment for Good Reason (as defined below) and provided such termination constitutes a “Separation from Service” (as defined under U.S. Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder) and such termination is not as a result of your death or disability, then in addition to the Accrued Obligations, you will be eligible to receive the following benefits:

(i)         You shall continue to receive your then-current base salary (ignoring any decrease that forms the basis for your termination for Good Reason, if applicable), less standard deductions and withholdings, for fifteen (15) months following the date of termination (the “Severance Period”).

(ii)         If you are eligible for and timely elect to continue your health insurance coverage under the Company’s group health plans under the Consolidated Omnibus Budget Reconciliation Act of 1985 or the state equivalent (“COBRA”), the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of (A) the end of the Severance Period, (B) the expiration of your eligibility for the continuation coverage under COBRA or (C) such time as you become employed by another employer or self-employed through which you are eligible for health insurance (thereafter, you will be responsible for all COBRA premium payments, if any) (such period from your termination date through the earliest of (A) through (C), the “COBRA Payment Period”). For purposes of this Section, references to COBRA premiums shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you elect health care continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the COBRA premiums would otherwise have been paid to you and shall be equal to the amount that the Company would have otherwise paid for COBRA premiums (which amount shall be calculated based on your COBRA premium for the first month of coverage), and shall be paid until the earlier of (i) expiration of the COBRA Payment Period or (ii) the date you voluntarily enroll in a health insurance plan offered by another employer or entity.

(iii)        If your termination occurs within one (1) month prior to or twelve (12) months following a Change in Control, you shall be eligible to receive the payments and benefits as described in the Company’s Change in Control Severance Benefit Plan (the “CIC Plan”) and the Participation Agreement thereunder (the “Participation Agreement”).  You must execute the Participation Agreement within the time frame set forth therein and comply with its terms to be eligible for such benefits.  If as a result of your termination or resignation you become entitled to severance benefits under the CIC Plan and you are also entitled to severance benefits described under Sections (i) and (ii) of the “Severance Eligibility” section of this Agreement above, the severance benefits under the CIC Plan shall be provided in lieu of the severance benefits you are entitled to under Sections (i) and (ii) of the “Severance Eligibility” section of this Agreement described above. 

Severance benefits under this Agreement are expressly conditioned upon (a) your delivery to the Company of a signed release and waiver of claims in such form as may be specified by the Company (or its successor) (the “Release”) within the applicable deadline set forth therein, and permitting the Release

4

February 2019

to become effective in accordance with its terms no later than the Release Deadline (as defined in the Section 409A Section below); and (b) your fully complying with your obligations under your Proprietary Information Agreement.

For the avoidance of doubt, you shall not be eligible for severance and continued benefits (other than the Accrued Obligations) if you are terminated by the Company for Cause (as defined herein), resign without Good Reason, or are terminated due to your death or disability.

Definitions: For purposes of this Agreement, the following terms “Good Reason” and “Change in Control” shall have the following meanings set forth in the CIC Plan.

Section 409A: Notwithstanding anything in this Agreement to the contrary, the following provisions apply to the extent severance benefits provided herein are subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”). Severance benefits shall not commence until you have a Separation from Service. Each installment of severance benefits is a separate “payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and you are, upon Separation from Service, a “specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day after your Separation from Service, or (ii) your death. You shall receive severance benefits only if you execute and return to the Company the Release within the applicable time period set forth therein and permit such Release to become effective in accordance with its terms, which date may not be later than sixty (60) days following the date of your Separation from Service (such latest permitted date, the “Release Deadline”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which your Separation from Service occurs, the Release will not be deemed effective any earlier than the Release Deadline. None of the severance benefits will be paid or otherwise delivered prior to the effective date of the Release. Except to the minimum extent that payments must be delayed because you are a “specified employee” or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the schedule provided herein and in accordance with the Company’s normal payroll practices.  All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods described in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.  The benefits under this Agreement are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.

Compliance with Rules, etc.:  You will comply at all times with (i) all Company policies, rules and procedures as they may be established, stated and/or modified from time to time at the Company’s sole discretion, (ii) the terms of any Proprietary Information Agreement that you sign with the Company, and (iii) all laws and regulations applicable to the Company’s business and your performance of your duties for the Company. 

5

February 2019

General:  By signing this letter, you acknowledge that the terms described in this letter, together with the Equity Documents and Proprietary Information Agreement attached hereto, set forth the entire offer to you and understanding between you and the Company and supersedes any prior representations or agreements, whether written or oral pertaining to the subject matter herein.  You further acknowledge that there are no terms, conditions, representations, warranties or covenants other than those contained herein. No term or provision of this letter may be amended waived, released, discharged or modified except in writing, signed by you and an authorized officer of the Company, except that the Company may, in its sole discretion, adjust salaries, incentive compensation, stock plans, benefits, job titles, locations, duties, responsibilities, and reporting relationships.

We look forward to your joining the Flexion team and becoming part of the energy and excitement to realize our business goals. Unless signed and accepted, this offer will expire three business days after the date of this letter.

Sincerely,

/s/Michael Clayman, M.D.

Michael Clayman, M.D.

Chief Executive Officer

ACCEPTED AND AGREED TO:

/s/Melissa Layman

Date:  January 20, 2020

                   cc:Christina Willwerth

6

February 2019